Workflow
Repligen (RGEN) Beats Q4 Earnings Estimates
RGENRepligen(RGEN) ZACKS·2025-02-20 14:45

Group 1 - Repligen reported quarterly earnings of 0.44pershare,exceedingtheZacksConsensusEstimateof0.44 per share, exceeding the Zacks Consensus Estimate of 0.41 per share, and up from 0.33pershareayearago,representinganearningssurpriseof7.320.33 per share a year ago, representing an earnings surprise of 7.32% [1] - The company posted revenues of 167.55 million for the quarter ended December 2024, slightly missing the Zacks Consensus Estimate by 0.10%, compared to 155.74millioninthesamequarterlastyear[2]−Overthelastfourquarters,RepligenhassurpassedconsensusEPSestimatestwotimesandtoppedconsensusrevenueestimatestwotimes[2]Group2−Thestock′simmediatepricemovementwilldependonmanagement′scommentaryduringtheearningscall,withRepligensharesgainingabout4.7155.74 million in the same quarter last year [2] - Over the last four quarters, Repligen has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Group 2 - The stock's immediate price movement will depend on management's commentary during the earnings call, with Repligen shares gaining about 4.7% year-to-date, compared to the S&P 500's gain of 4.5% [3] - The current consensus EPS estimate for the upcoming quarter is 0.37 on revenues of 163.53million,andforthecurrentfiscalyear,itis163.53 million, and for the current fiscal year, it is 1.71 on revenues of $695.77 million [7] - The Medical - Biomedical and Genetics industry, to which Repligen belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook [8]